PCT and MR-proADM

Utility to support decision making during COVID-19 and beyond

September 17, 2020, 11:45-12:30 CET

This symposium provides insights into the practical implementation of both biomarkers in the real-life management of COVID-19 patients.

  • Gain an understanding of the utility of Procalcitonin in the early identification of COVID-19 patients at low risk of bacterial coinfection and adverse outcomes.
  • Get to know new data on the prognostic significance of MR-proADM measured through hospital admissions of COVID-19 patients.
  • Go beyond COVID-19 and be the first to learn about the results of the interventional trial IDEAL and how MR-proADM can improve discharge decisions.


e-isicem-2020-speaker-m-mansourClinical utility of procalcitonin in the management of COVID-19 patients
Michael K. Mansour, Massachusetts General Hospital, Boston, USA

e-isicem-2020-speaker-p-schuetzPrognostic significance of MR-proADM admission levels in COVID-19 patients
Philipp Schuetz, Medizinische Universitätsklinik, Kantonsspital Aarau, Switzerland

e-isicem-2020-speaker-j-gonzalezImproving discharge in the ED: identifying patients with suspicion of infection in the ED who have low disease severity using MR-proADM
Juan González del Castillo, Hospital Clínico San Carlos, Madrid, Spain

  • Live Q & A

Register now! >

e-ISICEM website >

thermo scientific applied biosystems invitrogen fisher scientific unity lab service